Abstract CT212: Expanded phase 1/2a study of PLX8394, a novel next generation BRAF inhibitor in patients with advanced, unresectable solid tumors with alterations in BRAF

Autor:	Aparna Raj Parikh, Rona Yaeger, Gabi Tarcic, Michael Vidne, Filip Janku, Ryan J. Sullivan, Steven Averbuch, Kathe Balinski, Marc Rudoltz, Michael S. Gordon, Macarena I. de la Fuente, Eric J. Sherman, Carl E. Allen, Lynn G. Feun, Frank Tsai
Rok vydání:	2021
Předmět:	Cancer Research Oncology BRAF inhibitor business.industry Phase (matter) Cancer research Medicine In patient business
Zdroj:	Cancer Research. 81:CT212-CT212
ISSN:	1538-7445 0008-5472
Popis:	The authors did not submit an updated abstract. The original abstract should be considered final. Citation Format: Filip Janku, Eric Sherman, Rona Yaeger, Aparna Parikh, Ryan Sullivan, Lynn Feun, Macarena De La Fuente, Frank Yung-Chin Tsai, Michael Gordon, Carl Allen, Marc S. Rudoltz, Kathe Balinski, Steven Averbuch, Michael Vidne, Gabi Tarcic. Expanded phase 1/2a study of PLX8394, a novel next generation BRAF inhibitor in patients with advanced, unresectable solid tumors with alterations in BRAF [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr CT212.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::2a087809e83a25d26a2645e1245deba9 https://doi.org/10.1158/1538-7445.am2021-ct212 Zobrazit plný text záznamu